Literature DB >> 15668965

Is optic neuritis more benign than other first attacks in multiple sclerosis?

Mar Tintoré1, Alex Rovira, Jordi Rio, Carlos Nos, Elisensa Grivé, Neus Téllez, Raul Pelayo, Manuel Comabella, Xavier Montalban.   

Abstract

Optic neuritis presentations are thought to have a better prognosis. The aim of our study was to compare conversion to multiple sclerosis on the different topographies of CISs. We prospectively evaluated 320 patients with CISs (123 with optic neuritis, 78 with brainstem syndromes, 89 with spinal cord syndromes, and 30 with other topographies) who were observed for a median of 39 months. Patients underwent brain MRI within 3 months of their first attack and again 12 months later. Conversion to multiple sclerosis determined either clinically or by MRI was evaluated according to topography. Baseline MRI was normal in 49.2% of patients with optic neuritis compared with 24% in brainstem syndromes, 24% in spinal cord syndromes, and 18.5% in other syndromes. Optic neuritis behaved differently from the other CISs for lower conversion to clinically definite multiple sclerosis and smaller proportion of patients fulfilling MRI dissemination in space, time, or both. Nevertheless, when only patients with abnormal cranial MRI results at baseline were selected, no differences for clinical or MRI conversion were found. Optic neuritis has a smaller risk for conversion to multiple sclerosis. Nevertheless, MRI at baseline, not CIS topography, appears to be the crucial issue at multiple sclerosis presentation.

Entities:  

Mesh:

Year:  2005        PMID: 15668965     DOI: 10.1002/ana.20363

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  29 in total

Review 1.  Evidence in practice--number 8. What is the prognosis of optic neuritis? How often does it lead to multiple sclerosis?

Authors:  Sharon Sanders; Chris Del Mar; Sarah Purdy; Annelise Spinks; Lisa Tait; Brian McAvoy
Journal:  Br J Gen Pract       Date:  2005-12       Impact factor: 5.386

2.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

3.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

Review 4.  The Relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis.

Authors:  Rahşan Göçmen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

5.  Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis.

Authors:  Sara Lundqvist; Signe Modvig; Emilie A Fischer; Jette L Frederiksen; Matilda Degn
Journal:  Immunology       Date:  2018-12-27       Impact factor: 7.397

Review 6.  New directions in optic neuritis and multiple sclerosis.

Authors:  Molly E Gilbert; Robert C Sergott
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

7.  A three-year, multi-parametric MRI study in patients at presentation with CIS.

Authors:  Maria A Rocca; Federica Agosta; Maria P Sormani; Kryshani Fernando; Mar Tintorè; Tijmen Korteweg; Paola Tortorella; David H Miller; Alan Thompson; Alex Rovira; Xavier Montalban; Chris Polman; Frederik Barkhof; Massimo Filippi
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

8.  Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Authors:  Chris Polman; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederick Barkhof; Krzysztof Selmaj; Bernard M J Uitdehaag; Susanne Dahms; Lars Bauer; Christoph Pohl; Rupert Sandbrink
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

9.  A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease.

Authors:  Jessica Mandrioli; Patrizia Sola; Roberta Bedin; Mariaelena Gambini; Elisa Merelli
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

10.  Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship.

Authors:  Alexander Klistorner; H Arvind; T Nguyen; R Garrick; M Paine; S Graham; J O'Day; C Yiannikas
Journal:  Doc Ophthalmol       Date:  2008-09-09       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.